Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP Patrick R. O’neil sold 1,000 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $55.00, for a total transaction of $55,000.00. Following the completion of the sale, the senior vice president now directly owns 10,633 shares in the company, valued at approximately $584,815. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ionis Pharmaceuticals, Inc. (IONS) traded up 2.28% during trading on Thursday, reaching $56.43. 1,135,349 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $50.97 and its 200 day moving average price is $47.59. The firm has a market cap of $7.02 billion, a P/E ratio of 271.30 and a beta of 3.13. Ionis Pharmaceuticals, Inc. has a 52-week low of $24.58 and a 52-week high of $60.01.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.03. Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The company had revenue of $104.15 million during the quarter, compared to analyst estimates of $93.29 million. During the same quarter in the previous year, the business posted ($0.47) earnings per share. The company’s revenue for the quarter was up 170.7% on a year-over-year basis. Equities research analysts anticipate that Ionis Pharmaceuticals, Inc. will post ($0.19) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Ionis Pharmaceuticals, Inc. (IONS) SVP Sells 1,000 Shares of Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/09/07/insider-selling-ionis-pharmaceuticals-inc-ions-svp-sells-1000-shares-of-stock.html.

A number of analysts recently weighed in on IONS shares. TheStreet raised shares of Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, July 5th. BMO Capital Markets reissued a “buy” rating and issued a $59.00 target price on shares of Ionis Pharmaceuticals in a research note on Friday, June 2nd. Needham & Company LLC reissued a “buy” rating and issued a $64.00 target price on shares of Ionis Pharmaceuticals in a research note on Wednesday, May 17th. Leerink Swann reissued an “outperform” rating and issued a $45.00 target price (down previously from $47.00) on shares of Ionis Pharmaceuticals in a research note on Wednesday, May 17th. Finally, Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research note on Wednesday, July 12th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $49.31.

A number of large investors have recently bought and sold shares of the stock. Parallel Advisors LLC lifted its position in shares of Ionis Pharmaceuticals by 62.8% in the 2nd quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock worth $109,000 after purchasing an additional 800 shares during the period. Hanseatic Management Services Inc. bought a new stake in shares of Ionis Pharmaceuticals in the 1st quarter valued at $138,000. Westpac Banking Corp bought a new stake in shares of Ionis Pharmaceuticals in the 1st quarter valued at $171,000. The Manufacturers Life Insurance Company increased its stake in shares of Ionis Pharmaceuticals by 9.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after acquiring an additional 311 shares in the last quarter. Finally, WFG Advisors LP increased its stake in shares of Ionis Pharmaceuticals by 77.2% in the 2nd quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock valued at $193,000 after acquiring an additional 1,655 shares in the last quarter. Institutional investors and hedge funds own 89.32% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.